The US Food and Drug Administration (FDA) has approved a fixed-dose combination of extended-release niacin (Niaspan) and simvastatin for patients with complex lipid disorders who haven't responded to a statin or niacin alone.
The new medicine, Simcor (Abbott), lowers total and LDL cholesterol and raises HDL ("good") cholesterol. It was well tolerated, and the most common side effect was flushing.
Update: later large trials found that adding niacin to a statin didn't reduce heart attacks or strokes and caused more side effects, and the FDA withdrew approval of Simcor in 2016.
0
Like
0
Love
0
Angry
0
Dislike
0
